# Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

> **NCT04523571** · PHASE1 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 144 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** BNT162b1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04523571
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-28
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-08-10
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523571, "Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04523571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*